IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

Haematologica. 2023 Apr 1;108(4):1168-1172. doi: 10.3324/haematol.2022.281607.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Neutropenia* / genetics

Substances

  • Isocitrate Dehydrogenase